OverviewSuggest Edit

WuXi AppTec (药明康德) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs, and cell and gene therapies. It offers drug discovery, pre-clinical development, and clinical processes research, as well as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, toxicology, bioanalysis, and testing services. The company serves pharmaceutical, biotech, and medical device industries.
TypePublic
Founded2000
HQShanghai, CN
Websitewuxiapptec.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Jun 2020)22,824(+5%)
Revenue (FY, 2019)¥12.9 B(+34%)
Share Price (Jan 2021)¥176 (+10%)
Cybersecurity ratingAMore

Key People/Management at WuXi AppTec

Ge Li

Ge Li

Chairman and CEO
Ellis Chu

Ellis Chu

Senior Vice President, Chief Financial Officer
Yunxing Yin

Yunxing Yin

Vice President, WuXi AppTec CSU
Peter Tong

Peter Tong

Senior Vice President, Chief Operating Officer
Luyong Jiang

Luyong Jiang

Executive Director, WuXi AppTec CSU
Minzhang Chen

Minzhang Chen

Executive Vice President, CEO of STA
Show more

WuXi AppTec Office Locations

WuXi AppTec has offices in Shanghai, Changzhou Shi, Chengdu, Nantong and in 13 other locations
Shanghai, CN (HQ)
288 Fute Middle Rd, Pudong Xinqu
Changzhou Shi, CN
589 North Yulong Road, Xinbei District
Chengdu, CN
No.388 Haifa Road, Chengdu Cross-Strait Science & Technology Industrial Development Park, Wenjiang District
Nantong, CN
699 Huashi Nan Road, Qidong Economic Development Zone
Shanghai, CN
8F&19F, Building, 388 Madang Rd, Huangpu Qu
Shanghai, CN
9 Yuegong Rd, Jinshan Qu
Show all (24)

WuXi AppTec Financials and Metrics

WuXi AppTec Revenue

Embed Graph
View revenue for all periods
WuXi AppTec's revenue was reported to be ¥12.87 b in FY, 2019 which is a 33.9% increase from the previous period.
CNY

Revenue (H1, 2020)

7.2b

EBIT (H1, 2020)

1.9b

Market capitalization (22-Jan-2021)

427.1b

Closing stock price (22-Jan-2021)

176.0
WuXi AppTec's current market capitalization is ¥427.1 b.
Annual
CNYFY, 2017FY, 2018FY, 2019

Revenue

7.8b9.6b12.9b

Revenue growth, %

24%34%

Cost of goods sold

4.5b5.8b7.9b

Gross profit

3.2b3.8b5.0b
Half Year
CNYH1, 2018H1, 2019H1, 2020

Revenue

4.4b5.9b7.2b

Cost of goods sold

2.7b3.6b

Gross profit

1.8b2.3b

Gross profit Margin, %

40%39%
Annual
CNYFY, 2017FY, 2018FY, 2019

Cash

2.5b5.8b5.2b

Accounts Receivable

1.4b2.0b3.0b

Prepaid Expenses

22.0m42.8m24.0m

Inventories

649.8m854.8m1.2b
Half Year
CNYH1, 2019H1, 2020

Cash

3.7b

Accounts Receivable

2.5b

Prepaid Expenses

46.6m

Inventories

972.5m
Annual
CNYFY, 2017FY, 2018FY, 2019

Depreciation and Amortization

477.7m645.2m963.4m

Inventories

(200.2m)(207.0m)(378.9m)

Accounts Payable

98.4m254.2m618.8m

Cash From Operating Activities

1.8b1.5b2.5b
Half Year
CNYH1, 2018H1, 2019

Cash From Operating Activities

(3.7b)(2.6b)

Purchases of PP&E

(739.5m)(1.0b)

Long-term Borrowings

(700.5m)(192.6m)

Dividends Paid

(19.2m)(607.7m)
CNYFY, 2017

Revenue/Employee

526.0k

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.9 x
Show all financial metrics

WuXi AppTec Operating Metrics

WuXi AppTec's New Customers was reported to be 1.2 k in FY, 2019. WuXi AppTec's Active Customers was reported to be 3.9 k in FY, 2019.
FY, 2018FY, 2019

New Customers

1.40 k1.20 k

Active Customers

3.50 k3.90 k

DNA Encoded Library Compounds

80 b90 b

Customers (DNA Encoded Library) to Date

110
Show all operating metrics

WuXi AppTec Acquisitions / Subsidiaries

Company NameDateDeal Size
PharmapaceMay 05, 2019
ResearchPoint GlobalOctober 17, 2017
HD BiosciencesJanuary 19, 2017
CreluxApril 15, 2016
NextCODE HealthJanuary 09, 2015$65 m
Changzhou SynTheAll Pharmaceutical Co.
Shanghai STA Pharmaceutical R&D Co.
Shanghai SynTheAll Pharmaceutical Co.
STA Pharmaceutical Hong Kong Limited
WuXi AppTec (Chengdu) Co.
Show more

WuXi AppTec Revenue Breakdown

Embed Graph

WuXi AppTec revenue breakdown by business segment: 50.3% from China-based Laboratory Services, 12.1% from U.S.-based Laboratory Services, 8.3% from Clinical Research and Other CRO Services, 29.1% from CMO/CDMO Services and 0.2% from Other

WuXi AppTec revenue breakdown by geographic segment: 23.0% from China, 59.7% from United States, 11.9% from Europe and 5.3% from Other

Human Capital Metrics

WuXi AppTec's employees are reported to be approximately 82% female and 18% male.
Embed Graph
Show all human capital metrics

WuXi AppTec Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

WuXi AppTec Online and Social Media Presence

Embed Graph

WuXi AppTec News and Updates

Fitch Revises Outlook on WuXi AppTec to Positive, Affirms Ratings at 'BBB-'

Fitch Ratings has revised the Outlook on WuXi AppTec Co., Ltd.'s Long-Term Issuer Default Rating (IDR) to Positive from Stable and affirmed the IDR and senior unsecured rating at 'BBB-'.

WuXi AppTec Reports Strong Third-Quarter 2020 Results

WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patien…

WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

WuXi AppTec Second-Quarter 2020 Results Revenue Up 29.4% YoY to RMB4,044 Million Net Profit Attributable to Owners of the Company Up 111.0% YoY to RMB1,414 Million Diluted EPS Up 110.3% YoY to RMB0.61 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 43.1% YoY to...

WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia

SHANGHAI and SAN DIEGO, July 9, 2020 /PRNewswire/ -- WuXi AppTec is pleased to announce that they are about to launch the second session of the webinar series "Collaborations That Transform," highlighting the impact of partnerships in bringing effective therapies to patients. This...

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and gene therapy Contract Deve…

Drug Discovery Company insitro Raises $143 Million

insitro — a machine-learning driven drug discovery and development company — announced it has raised $143 million in an oversubscribed Series B financing. This round of funding was led by Andreessen Horowitz with participation from new investors Canada Pension Plan Investment Board (CPP Investments)…
Show more

WuXi AppTec Frequently Asked Questions

  • When was WuXi AppTec founded?

    WuXi AppTec was founded in 2000.

  • Who are WuXi AppTec key executives?

    WuXi AppTec's key executives are Ge Li, Ellis Chu and Yunxing Yin.

  • How many employees does WuXi AppTec have?

    WuXi AppTec has 22,824 employees.

  • What is WuXi AppTec revenue?

    Latest WuXi AppTec annual revenue is ¥12.9 b.

  • What is WuXi AppTec revenue per employee?

    Latest WuXi AppTec revenue per employee is ¥564 k.

  • Who are WuXi AppTec competitors?

    Competitors of WuXi AppTec include Hetero, Pharmaron and Astellas Pharma.

  • Where is WuXi AppTec headquarters?

    WuXi AppTec headquarters is located at 288 Fute Middle Rd, Pudong Xinqu, Shanghai.

  • Where are WuXi AppTec offices?

    WuXi AppTec has offices in Shanghai, Changzhou Shi, Chengdu, Nantong and in 13 other locations.

  • How many offices does WuXi AppTec have?

    WuXi AppTec has 24 offices.